Generate Biomedicines director plans $521K sale

Director Frances Arnold files a Rule 144 notice to sell 32,210 GENB common shares originally received as restricted stock compensation.

Rhea-AI Filing Summary

Generate Biomedicines, Inc. (GENB) is the issuer for which director Frances Arnold has filed a notice of proposed sale of common stock under Rule 144. The filing covers a planned sale of 32,210 shares of common stock, with an aggregate market value of $520,630.62, through Fidelity Brokerage Services LLC on NASDAQ around September 2, 2026.

The shares to be sold originated from restricted stock vesting from the issuer on September 23, 2020 as compensation. The notice also reports that Arnold sold 1,000 shares during the past three months for proceeds of $16,002.00. The form is signed by Joshua Schmitt as a duly authorized representative of Fidelity, acting as attorney-in-fact for Frances Arnold.

Key Figures

Shares proposed to be sold: 32,210 shares Aggregate market value of proposed sale: $520,630.62 Shares outstanding: 128,352,436 shares +4 more

7 metrics

Shares proposed to be sold 32,210 shares Common stock to be sold under Rule 144 through Fidelity Brokerage Services LLC

Aggregate market value of proposed sale $520,630.62 Value of 32,210 GENB common shares proposed for sale

Shares outstanding 128,352,436 shares GENB common stock outstanding as referenced in the Form 144

Past 3-month shares sold 1,000 shares GENB common shares sold by Frances Arnold on September 1, 2026

Proceeds from past 3-month sale $16,002.00 Total proceeds from the 1,000 GENB shares sold on September 1, 2026

Acquisition date of shares to be sold September 23, 2020 Date restricted stock vested as compensation from Generate Biomedicines

Approximate sale date September 2, 2026 Approximate date of proposed Rule 144 sale on NASDAQ

Key Terms

Rule 144, restricted stock vesting, aggregate market value, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Common | 09/23/2020 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregate market value financial

"Common | Fidelity Brokerage Services LLC ... | 520630.62"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

attorney-in-fact regulatory

"as attorney-in-fact for Frances Arnold."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose about GENB director Frances Arnold?

It discloses that director Frances Arnold plans to sell 32,210 shares of Generate Biomedicines common stock under Rule 144, with the sale to be executed through Fidelity Brokerage Services LLC on NASDAQ around September 2, 2026.

How many GENB shares are proposed to be sold and what is their value?

The notice covers a proposed sale of 32,210 shares of Generate Biomedicines common stock with an aggregate market value of $520,630.62, as reported in the Rule 144 filing.

What is the origin of the GENB shares being sold under this Form 144?

The shares were acquired through restricted stock vesting from Generate Biomedicines on September 23, 2020, categorized as compensation in the filing.

Has Frances Arnold sold GENB shares in the last three months?

Yes. The filing reports that Frances Arnold sold 1,000 shares of Generate Biomedicines common stock on September 1, 2026 for total proceeds of $16,002.00 during the past three months.

How many GENB shares are outstanding according to this Form 144?

The Form 144 reports that there are 128,352,436 shares of Generate Biomedicines common stock outstanding, providing context for the director’s proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:22 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:20 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001665419
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Generate Biomedicines, Inc.
SEC File Number	001-43165
Address of Issuer	101 SOUTH STREET, SUITE 900 SOMERVILLE MASSACHUSETTS 02143
Phone	888-469-0055
Name of Person for Whose Account the Securities are To Be Sold	ARNOLD FRANCES
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	32210	520630.62	128352436	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/23/2020	Restricted Stock Vesting	Issuer			32210	09/23/2020	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Frances Arnold 101 South Street Suite 900 Somerville MA 02143	Common	09/01/2026	1000	16002.00

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Frances Arnold.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)